Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 13c

August 11, 2016 8:06 AM EDT
Get Alerts BCLI Hot Sheet
Trade BCLI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.05), $0.13 better than the analyst estimate of ($0.18).

Second Quarter 2016 and Recent Highlights

  • Announced positive topline results from U.S. Phase 2 randomized, placebo controlled study of NurOwn in patients with ALS.
    • Study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated.
    • NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit.
    • Response rates (based on ALSFRS-R responder analysis) were higher in NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks.
    • Further evidence of biological effect was demonstrated by the increased levels of growth factors in the cerebrospinal fluid and decreased inflammatory markers observed after two weeks.
    • Results will be used to help determine the study population and design for a registration study investigating multiple doses of NurOwn in ALS.
    • Phase 2 study was conducted at three sites in the U.S: Massachusetts General Hospital, UMass Medical School and the Mayo Clinic.
  • Company was awarded $1.5 million in non-dilutive funding from Israel's Office of the Chief Scientist.
  • Mr. Chaim Lebovits, CEO, moderated a round table session on Brainstorm's NurOwn proprietary technology at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment